| First Author | Nikolaou K | Year | 2012 |
| Journal | Cancer Cell | Volume | 21 |
| Issue | 6 | Pages | 738-50 |
| PubMed ID | 22698400 | Mgi Jnum | J:189286 |
| Mgi Id | MGI:5445013 | Doi | 10.1016/j.ccr.2012.04.026 |
| Citation | Nikolaou K, et al. (2012) Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 21(6):738-50 |
| abstractText | The tumor suppressor cylindromatosis (CYLD) inhibits the NFkappaB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation of TGF-beta activated kinase 1 (TAK1) and c-Jun N-terminal kinase (JNK). This is followed by hepatic stellate cell and Kupffer cell activation, which promotes progressive fibrosis, inflammation, tumor necrosis factor (TNF) production, and expansion of hepatocyte apoptosis toward the central veins. At later stages, compensatory proliferation results in the development of cancer foci featuring re-expression of oncofetal hepatic and stem cell-specific genes. The results demonstrate that, in the liver, CYLD acts as an important regulator of hepatocyte homeostasis, protecting cells from spontaneous apoptosis by preventing uncontrolled TAK1 and JNK activation. |
